|
|
Venture Partner - Menlo Park, California
|
 |
Jeff Gold is a Venture Partner of Longitude Capital. He focuses on investments in medical devices.
Prior to Longitude, Mr. Gold was Chief Executive Officer of CryoVascular Systems, a medical device company developing
treatments for peripheral vascular disease, from 2001 to 2005. CryoVascular was acquired by Boston Scientific Corporation
in 2005. Between 1997 and 2000, Mr. Gold was COO and Executive Vice President of CardioThoracic Systems (NASDAQ: CTSI), a
medical device company focused on developing products to enable off-pump open-heart surgery. CTSI completed an IPO in 1996
and was subsequently acquired by Guidant Corporation. Prior to CTSI, Mr. Gold spent 18 years with Cordis Corporation, now
the primary cardiovascular device subsidiary of Johnson & Johnson, in a series of roles of increasing responsibility and scope.
He was the co-founder and President of Cordis Endovascular Systems, the company that initially focused on the international
neuroradiology market.
He currently serves on the Boards of Access Closure, AngioDynamics (NASDAQ: ANGO), and Velomedix.
He is a member of the Commercialization Advisory Board for the Cleveland Clinic and on the Executive Committee of the Center for
Entrepreneurship & Innovation at the University of Florida.
Mr. Gold holds an M.B.A. from the University of Florida and a B.S. in Engineering from Northeastern University, and is a graduate of GE's Manufacturing Management Program.
|
|
|
|
